283 related articles for article (PubMed ID: 12442695)
1. Parkinson's disease is a neuropsychiatric disorder.
Agid Y; Arnulf I; Bejjani P; Bloch F; Bonnet AM; Damier P; Dubois B; François C; Houeto JL; Iacono D; Karachi C; Mesnage V; Messouak O; Vidailhet M; Welter ML; Yelnik J
Adv Neurol; 2003; 91():365-70. PubMed ID: 12442695
[No Abstract] [Full Text] [Related]
2. Functional neuroanatomy of the basal ganglia in Parkinson's disease.
Wichmann T; DeLong MR
Adv Neurol; 2003; 91():9-18. PubMed ID: 12442660
[No Abstract] [Full Text] [Related]
3. The role of the subthalamic nucleus in the pathophysiology of Parkinson's disease.
Blandini F
Funct Neurol; 2001; 16(4 Suppl):99-106. PubMed ID: 11996537
[No Abstract] [Full Text] [Related]
4. Potential nondopaminergic drugs for Parkinson's disease.
Silverdale MA; Fox SH; Crossman AR; Brotchie JM
Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686
[No Abstract] [Full Text] [Related]
5. Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered.
Braak H; Del Tredici K
Exp Neurol; 2008 Jul; 212(1):226-9. PubMed ID: 18501351
[TBL] [Abstract][Full Text] [Related]
6. [Patterns of neuronal activity in the basal ganglia nucleus in parkinsonian patients with levodopa-induced dyskinesia].
Li XY; Zhuang P; Li YJ
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(23):1607-12. PubMed ID: 19035099
[TBL] [Abstract][Full Text] [Related]
7. Cellular principles underlying normal and pathological activity in the subthalamic nucleus.
Bevan MD; Atherton JF; Baufreton J
Curr Opin Neurobiol; 2006 Dec; 16(6):621-8. PubMed ID: 17084618
[TBL] [Abstract][Full Text] [Related]
8. The influence of the subthalamic nucleus upon the damage to the dopamine system following lesions of globus pallidus in rats.
Wright AK; Arbuthnott GW
Eur J Neurosci; 2007 Aug; 26(3):642-8. PubMed ID: 17634067
[TBL] [Abstract][Full Text] [Related]
9. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia.
Dexter DT; Sian J; Jenner P; Marsden CD
Adv Neurol; 1993; 60():273-81. PubMed ID: 8420143
[No Abstract] [Full Text] [Related]
10. [Movement disorders and basal ganglia function].
Dietrichs E
Tidsskr Nor Laegeforen; 2008 Sep; 128(17):1968-71. PubMed ID: 18787574
[TBL] [Abstract][Full Text] [Related]
11. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease.
Whitehouse PJ
Adv Neurol; 1987; 45():393-7. PubMed ID: 2881448
[No Abstract] [Full Text] [Related]
12. Basal ganglia oscillations and pathophysiology of movement disorders.
Rivlin-Etzion M; Marmor O; Heimer G; Raz A; Nini A; Bergman H
Curr Opin Neurobiol; 2006 Dec; 16(6):629-37. PubMed ID: 17084615
[TBL] [Abstract][Full Text] [Related]
13. Subthalamic oscillatory activities at beta or higher frequency do not change after high-frequency DBS in Parkinson's disease.
Foffani G; Ardolino G; Egidi M; Caputo E; Bossi B; Priori A
Brain Res Bull; 2006 Mar; 69(2):123-30. PubMed ID: 16533660
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of bilateral subthalamic nucleus (STN) stimulation in Parkinson's disease.
Erola T; Heikkinen ER; Haapaniemi T; Tuominen J; Juolasmaa A; Myllylä VV
Acta Neurochir (Wien); 2006 Apr; 148(4):389-94. PubMed ID: 16284705
[TBL] [Abstract][Full Text] [Related]
15. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
16. Neuroimaging of nonmotor features of Parkinson's disease.
Deblieck C; Wu AD
Rev Neurol Dis; 2008; 5(3):125-33. PubMed ID: 18838952
[TBL] [Abstract][Full Text] [Related]
17. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?
Kish SJ
Adv Neurol; 2003; 91():39-49. PubMed ID: 12442662
[No Abstract] [Full Text] [Related]
18. Basic research in substantia nigra and ventral tegmental area: clinical implications.
Stratta F; Bonci A; Calabresi P; Stefani A; Pisani A; Bernardi G; Mercuri NB
J Neural Transm Suppl; 1995; 45():47-55. PubMed ID: 8748608
[TBL] [Abstract][Full Text] [Related]
19. 300-Hz subthalamic oscillations in Parkinson's disease.
Foffani G; Priori A; Egidi M; Rampini P; Tamma F; Caputo E; Moxon KA; Cerutti S; Barbieri S
Brain; 2003 Oct; 126(Pt 10):2153-63. PubMed ID: 12937087
[TBL] [Abstract][Full Text] [Related]
20. Nondopaminergic neurons in Parkinson's disease.
Hirsch EC; Orieux G; Muriel MP; Francois C; Feger J
Adv Neurol; 2003; 91():29-37. PubMed ID: 12449099
[No Abstract] [Full Text] [Related]
[Next] [New Search]
